Comparative analysis of disability-adjusted life years (DALY) in people with diabetes mellitus between Central Java and Yogyakarta

Penulis

  • Akbar Eka Nugraha Departement of Pharmacy, Faculty of Medicine, Universitas Sebelas Maret, Surakarta 57126, Indonesia
  • Devi Yanthre Manurung Departement of Pharmacy, Faculty of Medicine, Universitas Sebelas Maret, Surakarta 57126, Indonesia

DOI:

https://doi.org/10.35814/jifi.v24i2.2069

Kata Kunci:

Diabetes mellitus, DALY, YLD, YLL

Abstrak

Diabetes mellitus (DM) is a non-communicable disease with an increasing health burden. Differences in disease burden in Indonesia can be attributed to various factors. Therefore, a comparative analysis of disease burden based on Disability-Adjusted Life Years (DALY) is needed to understand the differences in the epidemiological characteristics of DM in Central Java and Yogyakarta. This study is a comparative descriptive study with a quantitative approach using secondary data. DALY and its components were analyzed to observe trends, calculate the Compound Annual Growth Rate (CAGR), and statistically tested using independent t-test to assess differences in DALY values between Central Java and Yogyakarta. The values showed an increasing trend in both provinces during the observation period. Yogyakarta had significantly higher DALY values than Central Java, with an average DALY rate of 1062.48 in Yogyakarta and a DALY rate of 807.01 in Central Java (p < 0.05). The increase in illness burden was greater in Yogyakarta (2.38%) compared to Central Java (2.21%). The ratio of Years of Life Lost (YLL) exceeded that of Years Lived with Disability (YLD), signifying that diabetes mellitus (DM) exerted a more significant influence on untimely mortality than on disability. These results emphasize the need for regional health policies that focus on preventing premature death and strengthening early detection of DM.

Referensi

[1] K. L. Ong et al., “Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021,” The Lancet, vol. 402, no. 10397, pp. 203–234, 2023, doi: 10.1016/S0140-6736(23)01301-6.

[2] M. Wahidin et al., “Projection of diabetes morbidity and mortality till 2045 in Indonesia based on risk factors and NCD prevention and control programs,” Sci. Rep., vol. 14, no. 1, pp. 1–17, 2024, doi: 10.1038/s41598-024-54563-2.

[3] Badan Pusat Statistik, “Statistik Penduduk Lanjut Usia 2024,” Badan Pusat Statistik, vol. 21, no. 1, pp. 1–273, 2024, [Online]. Available: https://www.bps.go.id/id/publication/2024/12/31/a00d4477490caaf0716b711d/statistik-penduduk-lanjut-usia-2024.html

[4] P. Liamputtong, Handbook of Research Methods in Health Social Sciences. Singapore: Springer Nature, 2019. doi: 10.1007/978-981-10-5251-4_96.

[5] I. F. de A. Tonetto, M. H. B. Baptista, D. dos S. Gomides, and A. E. Pace, “Quality of life of people with diabetes mellitus,” Revista da Escola de Enfermagem, vol. 53, pp. 1–8, 2019, doi: 10.1590/S1980-220X2018002803424.

[6] K. Dulyapach, P. Ngamchaliew, P. Vichitkunakorn, P. Sornsenee, and K. Choomalee, “Prevalence and Associated Factors of Delayed Diagnosis of Type 2 Diabetes Mellitus in a Tertiary Hospital: A Retrospective Cohort Study,” Int. J. Public Health, vol. 67, Nov. 2022, doi: 10.3389/ijph.2022.1605039.

[7] G. Li et al., “Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study,” Lancet Diabetes Endocrinol., vol. 2, no. 6, pp. 474–480, 2014, doi: 10.1016/S2213-8587(14)70057-9.

[8] M. Alijanzadeh et al., “Availability and affordability of diabetes healthcare services associated with the frequency of diabetes-related complications,” BMC Health Serv. Res., vol. 24, no. 1, Dec. 2024, doi: 10.1186/s12913-024-12065-x.

[9] E. M. M. Gkrinia and A. Belančić, “A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes,” Apr. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/diabetology6040025.

[10] K. Jáuregui-Renaud et al., “Health-related quality of life related to diabetes multisensory deficits and derealization,” Sci. Rep., vol. 15, no. 1, Dec. 2025, doi: 10.1038/s41598-025-13356-x.

[11] J. Zhang et al., “Impact of COVID-19 infection on mortality, diabetic complications and haematological parameters in patients with diabetes mellitus: A systematic review and meta-Analysis,” BMJ Open, vol. 15, no. 3, Mar. 2025, doi: 10.1136/bmjopen-2024-090986.

[12] F. Al Rashdi, S. Al Harrasi, M. Al Ismaili, A. G. AL Yaaqubi, Z. Atwan, and C. Tabche, “The profound impact of COVID-19 on the control and care of diabetic patients: a comprehensive retrospective cohort study,” BMC Primary Care, vol. 25, no. 1, Dec. 2024, doi: 10.1186/s12875-024-02672-2.

[13] U. Religioni, R. Barrios-Rodríguez, P. Requena, M. Borowska, and J. Ostrowski, “Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life,” Jan. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/medicina61010153.

[14] F. Muin and A. E. Nugraha, “Barriers and facilitators of medication reconciliation through the Consolidated Framework for Implementation Research (CFIR): a systematic review,” JURNAL ILMU KEFARMASIAN INDONESIA, vol. 24, no. 1, pp. 56–66, Apr. 2026, doi: 10.35814/jifi.v24i1.2026.

[15] I. S. Larasati, E. Nurinda, A. S. Wulandari, N. Kusumawardani, S. Indrayana, and D. P. Amukti, “Adherence and blood pressure control in hypertensive patients: a cross-sectional study,” JURNAL ILMU KEFARMASIAN INDONESIA, vol. 24, no. 1, pp. 26–37, Apr. 2026, doi: 10.35814/jifi.v24i1.1641.

[16] Z. Ismail, W. Ibrahim, W. Ahmad, S. H. Hamjah, and I. Komang Astina, “The Impact of Population Ageing: A Review,” 2021. [Online]. Available: https://creativecommons.org/licenses/by-nc/4.0/

[17] M. Choi, J. K. Sempungu, E. H. Lee, and Y. H. Lee, “Living longer but in poor health: healthcare system responses to ageing populations in industrialised countries based on the Findings from the Global Burden of Disease Study 2019,” BMC Public Health, vol. 24, no. 1, Dec. 2024, doi: 10.1186/s12889-024-18049-0.

Unduhan

Diterbitkan

2026-08-31

Terbitan

Vol 24 No 2 (2026): JIFI

Bagian

Articles

Lisensi

Hak Cipta (c) 2026 JURNAL ILMU KEFARMASIAN INDONESIA

Creative Commons License

Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.